United Therapeutics Corporation $UTHR Shares Acquired by Gotham Asset Management LLC

Key Points

• Gotham Asset Management LLC increased its stake in United Therapeutics Corporation by 46.0%, acquiring an additional 28,163 shares, and now owns approximately 0.20% of the company, valued at $27.54 million.
• Analyst reports have led to several price target increases for United Therapeutics, with Jefferies Financial Group raising it from $432 to $564, and Bank of America from $314 to $463, reflecting strong market optimism.
• Despite these positive developments, United Therapeutics' stock fell by 2.8% recently, with the company posting Q2 EPS of $6.41, missing estimates, and reporting revenue growth of 11.7% year-over-year.

Gotham Asset Management LLC boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 46.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 89,342 shares of the biotechnology company's stock after buying an additional 28,163 shares during the quarter. Gotham Asset Management LLC owned approximately 0.20% of United Therapeutics worth $27,541,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after purchasing an additional 15,312 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock valued at $192,571,000 after purchasing an additional 4,145 shares in the last quarter. Assetmark Inc. lifted its holdings in United Therapeutics by 20.8% during the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock valued at $159,823,000 after purchasing an additional 89,290 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its holdings in United Therapeutics by 22.5% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company's stock valued at $147,278,000 after purchasing an additional 87,664 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in United Therapeutics by 1.9% during the fourth quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock valued at $165,490,000 after purchasing an additional 8,577 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 1.5%

UTHR stock traded down $5.90 on Monday, hitting $394.62. The company's stock had a trading volume of 623,780 shares, compared to its average volume of 865,507. The firm has a 50 day moving average of $309.83 and a two-hundred day moving average of $305.60. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The stock has a market cap of $17.80 billion, a price-to-earnings ratio of 15.40, a price-to-earnings-growth ratio of 6.11 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the company earned $5.85 EPS. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. The trade was a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher Causey sold 3,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $423.21, for a total transaction of $1,269,630.00. Following the completion of the transaction, the director directly owned 4,865 shares in the company, valued at $2,058,916.65. This represents a 38.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 106,181 shares of company stock valued at $35,537,239. 10.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday, September 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $429.62.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.